| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
																	BTIG analyst David Larsen reiterates Oncology Institute (NASDAQ:TOI) with a Buy and maintains $7 price target.
																	
																	Oncology Institute (NASDAQ:TOI) affirms FY2025 sales outlook from $460.000 million-$480.000 million to $460.000 million-$480.00...
																	The Oncology Institute (NASDAQ:TOI) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate ...
																	
																	
																	B. Riley Securities analyst Yuan Zhi initiates coverage on Oncology Institute (NASDAQ:TOI) with a Buy rating and announces P...
																	The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI"), one of the largest value-based oncology groups in the United States,...
																	-SEC Filing